Cardiac Myosin Inhibitors for Obstructive Hypertrophic Cardiomyopathy in Contemporary Clinical Practice

This symposium will provide heart failure specialists and care providers insights into the recent guidelines for the management of obstructive hypertrophic cardiomyopathy (HCM) from the ACC/AHA and the European Society of Cardiology. Specifically, the appropriate and practical use of cardiac myosin inhibitors in clinical practice will be highlighted by a diverse group of HCM specialists.

An accredited satellite program, provided by the HCM Society and supported through an independent educational grant from Bristol Myers Squibb